Loading
Latest filing published 11 Oct 2023 for Zynerba Pharmaceuticals, Inc.. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
No signal scores available.
This profile gathers the share dealings of Brian Rosenberger in Zynerba Pharmaceuticals, Inc., where the filings describe the role as senior executive. We count 7 filings; the first trade dates from 26 January 2022 and the latest from 10 October 2023.
The open-market record consists of 1 sale worth €6,967, with no purchase. Other entries cover 5 share grants. So far in 2023, the count stands at no purchases and 1 sale.
On 11 October 2023 came the latest disclosure, a transaction in Zynerba Pharmaceuticals, Inc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. Section 16 rules allow two business days to file each Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
7 of 7 declarations